非激素依赖性乳腺癌CerbB-2表达与P53、Ki-67的关系研究

Correlation of CerbB-2 to Ki-67 and P53 expressions in hormone-independent breast cancer

目的研究非激素依赖性乳腺癌CerbB-2表达与P53表达、Ki-67增殖指数的关系。方法 180例女性乳腺癌病人,根据ER和PR表达情况,将病人分为激素依赖组和非激素依赖组。激素依赖组包括ER(+)和(或)PR(+);非激素依赖组为ER和PR都为(-)。采用免疫化Envision二步法检测CerbB-2、P53、Ki-67单克隆抗体。C-erbB-2免疫组化不能明确C-erbB-2表达者29例,未进行进一步分析。研究剩余51例非激素依赖性乳腺癌和100例激素依赖性乳腺癌CerbB-2表达与P53表达、Ki-67增殖指数的关系。结果本组非激素依赖性乳腺癌CerbB-2阴性组Ki-67增殖指数明显高于激素依赖性乳腺癌CerbB-2阴性组,差异有统计学意义(P<0.05);而两者CerbB-2阳性时差异无统计学意义(P>0.05)。非激素依赖性乳腺癌CerbB-2阴性组P53表达显著高于激素依赖性乳腺癌CerbB-2阴性组,差异有统计学意义(P<0.01);而两者CerbB-2阳性时差异无统计学意义(P>0.05)。结论 CerbB-2阴性时非激素依赖性乳腺癌肿瘤细胞增殖活性明显高于激素依赖性乳腺癌,CerbB-2阴性时非激素依赖性乳腺癌P53表达明显高于激素依赖性乳腺癌,这是CerbB-2阴性时非激素依赖性乳腺癌恶性度高及预后差的重要原因。

Objective To investigate the relation of CerbB-2 with Ki-67 and P53 expressions in hormone-independent breast cancer.Methods A total of 180 patients with breast cancer were examined for the positivity to estrogen receptor（ER） and progesterone receptor（PR）,and subsequently divided into hormone-dependent group（positive for both ER and PR） and hormone-independent group（negative for both）.CerbB-2,Ki-67 and P53 expressions were detected in these patients using an improved Envision immunohistochemical staining with the corresponding antibodies.Twenty-nine patients without definite immunohistochemical results of C-erbB-2 were excluded from further analysis.The 51 hormone-independent and 100 hormone-dependent cases were analyzed for the correlation of CerbB-2 to Ki-67 and P53 expressions.Results In hormone-independent cases negative for CerbB-2,Ki-67 and P53 expressions were significantly higher than that in hormone-dependent CerbB-2-negative cases（P0.05）,but in CerbB-2-positive cases,their expressions showed no significant differences（P0.05） with respect to hormonal dependence.Conclusions In hormone-independent CerbB-2-negative cases,the tumor cells show a higher proliferative activity and P53 expression than those in hormone-dependent cases,which can be an important reason for the high malignancy and poor prognosis of hormone-independent breast cancer negative for CerbB-2.